ImmunoSig

ImmunoSig operates as a specialized Contract Research Organization (CRO) leveraging a proprietary immunoprofiling platform that integrates high-density antigen microarrays with AI/ML analytics. The company serves vaccine and biologics developers, offering services to map immune responses, predict immunogenicity, and prioritize antigens, particularly for complex targets like bacterial pathogens. Founded by academic and industry scientists with deep expertise in immunology and protein science, ImmunoSig is positioned to address a critical bottleneck in modern immunology R&D. Its business model is service-based, targeting biopharma clients seeking to de-risk and optimize their development programs.

Integrated platform combining custom peptide/protein microarrays for high-throughput antibody binding detection with machine learning/AI analytics for immunoprofiling, epitope mapping, and immunogenicity prediction.

ImmunoSig competes with other specialty CROs and academic service centers offering high-plex immunology assays, such as Luminex-based multiplexing, phage display, and next-generation sequencing for B-cell receptor repertoire. Its key differentiators are the integration of custom microarrays with dedicated AI/ML for actionable insights and a focus on complex, multi-antigen challenges in vaccines and biologics.